Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model
Combining immune-boosting antibodies with magnetic nanoparticle heat treatment eradicated bladder tumors in most treated mice, suggesting a minimally invasive combination strategy worth pursuing.
In a murine bladder cancer model, combining anti-PD-L1 antibody-conjugated magnetoliposomes with a single-session low-temperature magnetic hyperthermia achieved complete tumor regression in 80% of animals, compared to no regressions with hyperthermia alone at the same dose — mediated through enhanced CD8+ T cell infiltration. While preclinical, the combination of immunotherapy checkpoint blockade with nanoparticle-mediated hyperthermia represents a promising minimally invasive local-plus-systemic strategy warranting further development.
What the study was
- Study design
- Animal model (murine subcutaneous bladder cancer, n=5 per group)
- Population
- Murine MB49 bladder cancer model (C57BL/6)
- Sample size
- 5
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International Journal of Hyperthermia
Why it surfaced
Novel combination approach (nanoparticle-mediated hyperthermia + PD-L1 blockade) with strong preclinical signal in bladder cancer; capped at score 5 per non-human study rule.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.